The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Intravenous Glucocorticoids for Graves' Orbitopathy: Efficacy and Morbidity
Abstract
CONTEXT: The administration of iv glucocorticoid pulses has been advocated as a treatment approach for patients with inflammatory and moderate to severe Graves' orbitopathy (GO). This review offers an update on this controversial regimen. EVIDENCE ACQUISITION: PubMed and the MeSH-Database were searched (with no temporal limit) for the following topics: management of active and severe GO; glucocorticoid therapy of GO; iv glucocorticoid administration; mechanism and pharmacokinetics of iv glucocorticoids; and adverse events, morbidity, and mortality of iv glucocorticoids. The articles were evaluated according to their setting and study design. EVIDENCE SYNTHESIS: All randomized and uncontrolled trials, consensus statement, systematic reviews, and meta-analyses dealing with the efficacy and morbidity of iv glucocorticoids in GO were identified. CONCLUSIONS: The current first-line treatment for active, moderate-to-severe GO is a 12-wk course of high-dose iv glucocorticoid pulses. The response rate of this regimen is approximately 80%. Intravenous glucocorticoids have a statistically significant advantage over oral treatment and cause significantly fewer adverse events. However, major side effects related to preexisting diseases, administered dose, and treatment schedule have been reported. The morbidity and mortality of iv glucocorticoid therapy are 6.5 and 0.6%, respectively. Thus, careful patient selection is warranted. Before iv glucocorticoid administration, patients should be screened for recent hepatitis, liver dysfunction, cardiovascular morbidity, severe hypertension, inadequately managed diabetes, and glaucoma. The cumulative dose should not exceed 8 g, and with the exception of sight-threatening GO the single doses preferably should not be administered on consecutive days. Monthly monitoring during subsequent treatment is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO
Bartalena, L., Baldeschi, L., Dickinson, A., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0666 · Cited by 795
Self-citationMourits, M. P., Koornneef, L., Wiersinga, W. M., Prummel, M. F., Berghout, A., & van der Gaag, R. (1989) · British Journal of Ophthalmology · doi:10.1136/bjo.73.8.639 · Cited by 721
Brent, G. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0801880 · Cited by 594
Randomized, Single Blind Trial of Intravenous versus Oral Steroid Monotherapy in Graves’ Orbitopathy
Kahaly, G. J., Pitz, S., Hommel, G., & Dittmar, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0148 · Cited by 423
Self-citationBartalena, L., Baldeschi, L., Dickinson, A. J., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M. P., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · Thyroid · doi:10.1089/thy.2007.0315 · Cited by 406
Self-citationBartalena, L., & Tanda, M. L. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0806317 · Cited by 336
Randomised double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy
Prummel, M. F., Berghout, A., Wiersinga, W. M., Mourits, M. P., Koornneef, L., & Blank, L. (1993) · The Lancet · doi:10.1016/0140-6736(93)92001-a · Cited by 332
Bartalena, L., Marcocci, C., Bogazzi, F., Panicucci, M., Lepri, A., & Pinchera, A. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212001 · Cited by 318
Marcocci, C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3562 · Cited by 309
Cigarette Smoking and Treatment Outcomes in Graves Ophthalmopathy
Bartalena, L., Marcocci, C., Tanda, M. L., Manetti, L., Dell'Unto, E., Bartolomei, M. P., Nardi, M., Martino, E., & Pinchera, A. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-8-199810150-00010 · Cited by 295
Cited by
Smith, T. J., & Hegedüs, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510030 · Cited by 1,257
Bartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., Perros, P., Salvi, M., & Wiersinga, W. M. (2016) · European Thyroid Journal · doi:10.1159/000443828 · Cited by 943
Self-citationTeprotumumab for Thyroid-Associated Ophthalmopathy
Smith, T. J., Kahaly, G. J., Ezra, D. G., Fleming, J. C., Dailey, R. A., Tang, R. A., Harris, G. J., Antonelli, A., Salvi, M., Goldberg, R. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614949 · Cited by 756
Self-citationDavies, T. F., Andersen, S., Latif, R., Nagayama, Y., Barbesino, G., Brito, M., Eckstein, A. K., Stagnaro-Green, A., & Kahaly, G. J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0184-y · Cited by 398
Self-citationPerez-Moreiras, J. V., Gomez-Reino, J. J., Maneiro, J. R., Perez-Pampin, E., Romo Lopez, A., Rodríguez Alvarez, F. M., Castillo Laguarta, J. M., del Estad Cabello, A., Gessa Sorroche, M., España Gregori, E., et al. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.07.038 · Cited by 300
Metadata
- Authors
- Zang, S., Ponto, K. A., & Kahaly, G. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02
- Volume
- 96
- Issue
- 2
- Pages
- 320-332
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2052463348
- Cited by
- 379
- References
- 54
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous Glucocorticoids for Graves' Orbitopathy: Efficacy and Morbidity. https://app.cochat.ai/papers/10.1210/jc.2010-1962
- The paper
- Zang, S., Ponto, K. A., & Kahaly, G. J. (2011). Intravenous Glucocorticoids for Graves' Orbitopathy: Efficacy and Morbidity. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2010-1962
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
